How to buy Kadmon stock

Kadmon Holdings, Inc is a biotechnology business based in the US. Kadmon shares (KDMN) are listed on the NASDAQ and all prices are listed in US Dollars. Kadmon employs 127 staff and has a trailing 12-month revenue of around 0.00.

Kadmon share price

Use our graph to track the performance of KDMN stocks over time.

Kadmon shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$3.15 - $5.73
50-day moving average	$3.97
200-day moving average	$4.21
Wall St. target price	$12.17
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.37

Buy Kadmon shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Kadmon stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Kadmon Holdings, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kadmon financials

Revenue TTM	$8.3 million
Gross profit TTM	$6.3 million
Return on assets TTM	-33.87%
Return on equity TTM	-77.31%
Profit margin	0%
Book value	$0.42
Market capitalisation	$701 million

TTM: trailing 12 months

Shorting Kadmon shares

There are currently 43.7 million Kadmon shares held short by investors – that's known as Kadmon's "short interest". This figure is 4.9% up from 41.7 million last month.

There are a few different ways that this level of interest in shorting Kadmon shares can be evaluated.

Kadmon's "short interest ratio" (SIR)

Kadmon's "short interest ratio" (SIR) is the quantity of Kadmon shares currently shorted divided by the average quantity of Kadmon shares traded daily (recently around 3.6 million). Kadmon's SIR currently stands at 12.18. In other words for every 100,000 Kadmon shares traded daily on the market, roughly 12180 shares are currently held short.

However Kadmon's short interest can also be evaluated against the total number of Kadmon shares, or, against the total number of tradable Kadmon shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kadmon's short interest could be expressed as 0.25% of the outstanding shares (for every 100,000 Kadmon shares in existence, roughly 250 shares are currently held short) or 0.2687% of the tradable shares (for every 100,000 tradable Kadmon shares, roughly 269 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kadmon.

Find out more about how you can short Kadmon stock.

Kadmon share dividends

We're not expecting Kadmon to pay a dividend over the next 12 months.

Kadmon share price volatility

Over the last 12 months, Kadmon's shares have ranged in value from as little as $3.145 up to $5.73. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kadmon's is 1.5599. This would suggest that Kadmon's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Kadmon overview

Kadmon Holdings, Inc. , a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp.

Frequently asked questions

• What percentage of Kadmon is owned by insiders or institutions?

  Currently 0.144% of Kadmon shares are held by insiders and 97.568% by institutions.

• How many people work for Kadmon?

  Latest data suggests 127 work at Kadmon.

• When does the fiscal year end for Kadmon?

  Kadmon's fiscal year ends in December.

• Where is Kadmon based?

  Kadmon's address is: 450 East 29th Street, New York, NY, United States, 10016

• What is Kadmon's ISIN number?

  Kadmon's international securities identification number is: US48283N1063

• What is Kadmon's CUSIP number?

  Kadmon's Committee on Uniform Securities Identification Procedures number is: 48283N106